STAT3 and hepatocellular carcinoma: Regorafenib has been shown to downregulate this pathway by directly relieving the autoinhibited N-Src homology region 2 (SH2) domain of SH2 domain-containing phosphatase 1 (SHP-1), a negative regulator of STAT3, in both in vitro and in vivo HCC models25.